Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2).
James SunBrian R GastmanLucy McCahonElizabeth I BuchbinderIgor PuzanovMichele NanniJames M LewisRichard D CarvajalShahnaz Singh-KandahAnupam M DesaiLeon RaskinCarrie M NielsonRubina IsmailJonathan S ZagerPublished in: Melanoma management (2020)
In real-world settings, T-VEC may be used concurrently with or after anti-PD-1-based therapy.
Keyphrases